Albireo Sets Sights On Rare Disease Model
First Indication Under Review, With Plans For Two More
Anticipating approval this summer of the first drug for PFIC, Albireo hopes to add Alagille syndrome and biliary atresia to odevixibat labeling. Firm has modeled its commercial plans on the success of other rare disease firms.
You may also be interested in...
The company anticipates an addressable global market for progressive familial intrahepatic cholestasis of 2,500 patients, with initial plans to focus on around 100 physicians at 60 centers.
Some analysts are suggesting that AstraZeneca is getting hold of a "scarce and high-quality asset" in Alexion for a very reasonable price and shareholders could demand more than the $175 per share offer on the table.
Patients with the rare condition progressive familial intrahepatic cholestasis (PFIC) look set to have two possible therapeutic choices if recent filings for two IBAT inhibitors are successful.